Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VitiGam
- Development stage
- Discontinued
- Lead developer
- GammaCan
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VitiGam is a first-in-class immunoglobulin G (IgG)-based anticancer immunotherapy developed by GammaCan International for the treatment of stage IIB to stage IV metastatic melanoma. The drug is a biologic therapy manufactured from the plasma of donors with vitiligo, a benign skin condition characterized by the immune-mediated loss of melanocytes. VitiGam contains naturally occurring anti-melanoma antibodies (IgG) that have demonstrated the ability to bind to melanoma cells, inhibiting their proliferation and preventing metastasis in preclinical models. The drug received FDA orphan drug designation in July 2007; however, its development was subsequently halted following the financial dissolution of its developer.
- Brand names
- VitiGam
02
Targets
MAA (Macroaggregated albumin)GD3 (Ganglioside GD3)
Beyond the preview
Go deeper on VitiGam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VitiGam.